Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases

The Role of FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases: Non-randomized Phase II Molecular Imaging Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET/CT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery

Who May Be Eligible (Plain English)

Who May Qualify: - Age above 18 years. - Liver metastasis on standard imaging for the initial assessment (MRI, FDG PET/CT) - Naïve for treatment or after neoadjuvant chemotherapy - Scheduled for liver metastasis resection - ECOG Performance status ≤2. - Signed written willing to sign a consent form Who Should NOT Join This Trial: - Non-resectable liver metastases - Pregnant and lactating women - Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age above 18 years. * Liver metastasis on standard imaging for the initial assessment (MRI, FDG PET/CT) * Naïve for treatment or after neoadjuvant chemotherapy * Scheduled for liver metastasis resection * ECOG Performance status ≤2. * Signed written informed consent Exclusion Criteria: * Non-resectable liver metastases * Pregnant and lactating women * Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.

Treatments Being Tested

DIAGNOSTIC_TEST

FAPI PET/CT

Patient will undergo FAPI PET/CT Prior to surgery

Locations (1)

Institut Jules Bordet
Brussels, Belgium